Teva Completes $13.5 Million Investment in Andromeda, Gaining Exclusive Rights to Commercialize DiaPep277

Strategic Insights

Jul 5, 2009 — 1 min read

Teva Pharmaceutical Industries Ltd. has completed a $13.5 million investment in Andromeda Biotech Ltd., securing a worldwide exclusive license to commercialize DiaPep277, a potential treatment for Type 1 diabetes. The investment marks a significant milestone in the development of DiaPep277, which is currently in Phase III clinical studies. This move will accelerate the product's launch and provide Teva with a significant market share in the treatment of Type 1 diabetes.

Key Takeaways:

Teva Pharmaceutical Industries Ltd. has completed a $13.5 million investment in Andromeda Biotech Ltd., gaining exclusive rights to commercialize DiaPep277.
DiaPep277 is a potential treatment for Type 1 diabetes, which affects approximately 1% of the world's population.
The investment will fund the completion of a Phase III study, with results expected to be announced soon.
Andromeda's DiaPep277 has the potential to address the significant unmet medical need for a treatment for Type 1 diabetes, with an estimated potential market of over half a billion dollars per year.
Teva now has a significant stake in the development and commercialization of DiaPep277, with worldwide marketing rights for the product.
The partnership between Teva and Andromeda will accelerate the development of DiaPep277 and provide a potential solution for millions of people affected by Type 1 diabetes.

Statistics:

$13.5 million - The amount invested by Teva in Andromeda Biotech Ltd.
1% - The percentage of the population affected by Type 1 diabetes.
40 - The number of medical centers participating in the Phase III study of DiaPep277.
Over half a billion dollars - The estimated market potential for DiaPep277.
5 years - The maximum duration of the license agreement between Teva and Andromeda.

Sources:

"Teva Completes $13.5 million Investment in Andromeda and Receives Exclusive Rights to Commercialize DiaPep277" - Andromeda Biotech Ltd. (www.andromedabio.com)
"Type 1 Diabetes" - Andromeda Biotech Ltd. (www.andromedabio.com)
NewsRx.com - "Diabetes Week Via" (2009)

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients